Drug Trial Radar · NCT06305780
RECOVER-AUTONOMIC Platform Protocol
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
381
Actual
Start
Mar 11, 2024
Primary completion
Jul 9, 2025
Study completion Jul 9, 2025
Sponsor
- Lead sponsor
- Kanecia Obie ZimmermanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.
Conditions
- Long COVID
- Long Covid19
- Long Covid-19
Interventions
IVIG + Coordinated CareDrug
Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
IVIG Placebo + Coordinated CareDrug
Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration. Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
Ivabradine + Coordinated CareDrug
Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
Ivabradine Placebo + Coordinated CareDrug
The control (placebo) oral tablets will be similar to the study drug, ivabradine. The control packaging matches the packaging. Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator.
IVIG + Usual CareDrug
Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
IVIG Placebo + Usual CareDrug
Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG. Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration.
Ivabradine + Usual CareDrug
Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
Ivabradine Placebo + Usual CareDrug
The control (placebo) oral tablets will be similar to the study drug, ivabradine. The control packaging matches the packaging. Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Number of Participants Enrolled in Each AppendixTime frame: During the enrollment period, approximately 16 months
Locations
50 sites in 1 country. Site status is shown where the registry gives one.
East Alabama Medical Center - Appendix B Only
Opelika, Alabama
Center for Complex Neurology - Appendix A & B
Phoenix, Arizona
University of Arkansas for Medical Sciences - Appendix A & B
Little Rock, Arkansas
University of California San Diego - Appendix B Only
La Jolla, California
Cedars Sinai Medical Center - Appendix A & B
Los Angeles, California
Stanford University - Appendix B Only
Stanford, California
University of Colorado Anschutz Medical Campus Clinical and Translational Research Center (CTRC) - Appendix A & B
Aurora, Colorado
MedStar National Rehabilitation Hospital - Appendix B only
Washington D.C., District of Columbia
University of Florida Health - Appendix A & B
Gainesville, Florida
Lakeland Regional Medical Center - Appendix A & B
Lakeland, Florida
Innovation Clinical Trials Inc.- Appendix A & B
Palmetto Bay, Florida
Grady Memorial Hospital - Woodruff Memorial Research - Appendix A & B
Atlanta, Georgia
Morehouse School of Medicine - Appendix A & B
Atlanta, Georgia
Queens Medical Center - Appendix B Only
Honolulu, Hawaii
Rush University Medical Center - Appendix B Only
Chicago, Illinois
University of Illinois at Chicago - Appendix A & B
Chicago, Illinois
NorthShore University HealthSystem - Evanston Hospital - Appendix B Only
Evanston, Illinois
University of Iowa - Appendix A & B
Iowa City, Iowa
University of Kansas Medical Center CTSU Fairway - Appendix A & B
Fairway, Kansas
University of Kentucky Medical Center - Appendix A & B
Lexington, Kentucky
University Medical Center New Orleans - Appendix A & B
New Orleans, Louisiana
Johns Hopkins Hospital - Appendix A Only
Baltimore, Maryland
Brigham and Women's Hospital - Appendix A Only
Boston, Massachusetts
Henry Ford Hospital - Appendix A & B
Detroit, Michigan
Mayo Clinic - Appendix A & B
Rochester, Minnesota
University of Mississippi Medical Center - Appendix A & B
Jackson, Mississippi
Washington University School of Medicine - Appendix B Only
St Louis, Missouri
University at Buffalo - Appendix A & B
Buffalo, New York
St. Lawrence Health Medical Campus - Appendix A & B
Canton, New York
Columbia University Irving Medical Center - Appendix A & B
New York, New York
Stony Brook University Hospital - Appendix A & B
Stony Brook, New York
Montefiore Medical Center - Moses Campus - Appendix B
The Bronx, New York
Duke University Hospital - Appendix A & B
Durham, North Carolina
East Carolina University - Appendix B Only
Greenville, North Carolina
Cleveland Clinic - Appendix A & B
Cleveland, Ohio
University of Oklahoma Health Science Center - Oklahoma Clinical and Translational Science Institute - Appendix A & B
Oklahoma City, Oklahoma
Oregon Health and Science University - Appendix A & B
Portland, Oregon
Kent Hospital - Appendix A & B
Pawtucket, Rhode Island
Vanderbilt University Medical Center
Nashville, Tennessee
National Neuromuscular Research Institute - Appendix A & B
Austin, Texas
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.